- Home
- MYO vs RNXT Comparison
MYO vs RNXT Comparison
Compare MYO & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYO
- RNXT
- Stock Information
- Founded
- MYO 2004
- RNXT 2012
- Country
- MYO United States
- RNXT United States
- Employees
- MYO N/A
- RNXT N/A
- Industry
- MYO Industrial Specialties
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- MYO Health Care
- RNXT Health Care
- Exchange
- MYO Nasdaq
- RNXT Nasdaq
- Market Cap
- MYO 44.6M
- RNXT 43.2M
- IPO Year
- MYO 2017
- RNXT 2021
- Fundamental
- Price
- MYO $1.04
- RNXT $1.21
- Analyst Decision
- MYO Strong Buy
- RNXT Strong Buy
- Analyst Count
- MYO 3
- RNXT 2
- Target Price
- MYO $7.83
- RNXT $7.50
- AVG Volume (30 Days)
- MYO 2.0M
- RNXT 851.1K
- Earning Date
- MYO 11-05-2025
- RNXT 11-12-2025
- Dividend Yield
- MYO N/A
- RNXT N/A
- EPS Growth
- MYO N/A
- RNXT N/A
- EPS
- MYO N/A
- RNXT N/A
- Revenue
- MYO $40,760,091.00
- RNXT $662,000.00
- Revenue This Year
- MYO $25.69
- RNXT $2,895.35
- Revenue Next Year
- MYO $23.52
- RNXT $313.04
- P/E Ratio
- MYO N/A
- RNXT N/A
- Revenue Growth
- MYO 93.08
- RNXT N/A
- 52 Week Low
- MYO $0.80
- RNXT $0.75
- 52 Week High
- MYO $7.17
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- MYO 49.48
- RNXT 49.85
- Support Level
- MYO $0.87
- RNXT $1.24
- Resistance Level
- MYO $1.07
- RNXT $1.42
- Average True Range (ATR)
- MYO 0.08
- RNXT 0.10
- MACD
- MYO 0.04
- RNXT -0.00
- Stochastic Oscillator
- MYO 81.95
- RNXT 22.48
About MYO Myomo Inc.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.